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As mesenchymal stem cells (MSCs) are being investigated for regenerative therapies to be used in the clinic, delineating the roles of
the IGF system in MSC growth and diﬀerentiation, in vitro, is vital in developing these cellular therapies to treat degenerative
diseases. Muscle diﬀerentiation is a multistep process, starting with commitment to the muscle lineage and ending with the
formation of multinucleated ﬁbers. Insulin-like growth factor binding protein-6 (IGFBP-6), relative to other IGFBPs, has high
aﬃnity for IGF-2. However, the role of IGFBP-6 in muscle development has not been clearly deﬁned. Our previous studies
showed that in vitro extracellular IGFBP-6 increased myogenesis in early stages and could enhance the muscle diﬀerentiation
process in the absence of IGF-2. In this study, we identiﬁed the signal transduction mechanisms of IGFBP-6 on muscle
diﬀerentiation by placental mesenchymal stem cells (PMSCs). We showed that muscle diﬀerentiation required activation of both
AKT and MAPK pathways. Interestingly, we demonstrated that IGFBP-6 could compensate for IGF-2 loss and help enhance the
muscle diﬀerentiation process by triggering predominantly the MAPK pathway independent of activating either IGF-1R or the
insulin receptor (IR). These ﬁndings indicate the complex interactions between IGFBP-6 and IGFs in PMSC diﬀerentiation into
the skeletal muscle and that the IGF signaling axis, speciﬁcally involving IGFBP-6, is important in muscle diﬀerentiation.
Moreover, although the major role of IGFBP-6 is IGF-2 inhibition, it is not necessarily the case that IGFBP-6 is the main
modulator of IGF-2.

1. Introduction
Skeletal muscle comprises one-half of the human body [1].
The development of skeletal muscle is a complex multistep
process, starting with the generation of myogenic precursors
from mesodermal stem cells and ending with terminal diﬀerentiation and the commitment of myoblasts into myoﬁbers
[2]. During myogenesis, muscle stem cells commit to the

muscle lineage by upregulating muscle commitment markers
(Pax3/7). As Pax3/7 subsequently decreases, early muscle differentiation markers (MyoD and Myogenin) begin to be
expressed [3]. The committed muscle cells then start to fuse
and form multinucleated ﬁbers, which express the late muscle diﬀerentiation marker, myosin heavy chain (MHC) [3].
During muscle repair, a similar process is thought to occur
whereby satellite cells become activated, migrate towards
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Figure 1: Continued.
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Figure 1: PMSCs treated with the IGF-1R inhibitor, PPP, decreased potency-associated and muscle diﬀerentiation markers. (a) PPP
treatment decreased IGFBP-6 protein levels at day 14 as compared to the PMSCs grown in muscle diﬀerentiation media only. IGFBP-6
supplementation with PPP increased IGFBP-6 levels at 1 and 14 days compared to PPP alone. PPP treatment also decreased the protein
levels of the potency-associated markers (b) OCT4 and (c) SOX2. When IGFBP-6 was added with PPP, OCT4 levels increased at 14 days.
(d) PPP treatment decreased the protein levels of muscle lineage commitment marker Pax3/7 at 7 and 14 days. IGFBP-6 supplementation
with PPP increased Pax3/7 from 3 to 14 days compared to PPP alone. (e, f) Levels of the muscle diﬀerentiation markers, MyoD and
MyoG, were decreased at 7 and 14 days, and adding IGFBP-6 with PPP reversed these eﬀects. (g) Conversely, MHC protein levels were
reduced with PPP treatment at all time points compared to muscle diﬀerentiation. IGFBP-6 supplementation with PPP increased MHC
levels from 3 to 14 days compared to PPP alone. Protein levels were quantiﬁed by densitometry and normalized to β-actin. Data is
presented as the mean ± SEM of 3 independent experiments from one preterm placenta. Two-way ANOVA with Bonferroni’s multiple
comparison test was performed to determine ∗ P < 0 05, ∗∗ P < 0 01, and ∗∗∗ P < 0 001 compared to muscle diﬀerentiation conditions
or # P < 0 05, ## P < 0 01, and ### P < 0 001 compared to PPP.

injured muscle, and begin the diﬀerentiation process to
replace injured myoﬁbers [4].
IGFs are important components of the skeletal muscle
microenvironment and are required for muscle growth during development and regeneration after injury [1, 5, 6]. IGFs
regulate MyoD and Myogenin gene expressions, but the
mechanism is not completely understood [1]. When mice
are injected with IGF-1, there is an enhancement in muscle
mass (hypertrophy) [7, 8]. Moreover, IGF-1R null mice show
profound muscle hypoplasia and die prematurely soon after
birth due to breathing diﬃculties resulting from atrophy of
diaphragm and respiratory muscles [9].
Following the binding of IGFs to IGF-1R or IR, IRS-1 and
IRS-2 are phosphorylated, and then PI3K-AKT-mTOR and
MAPK pathways are activated [10]. Therefore, crosstalk
between the diﬀerent receptor tyrosine kinase (RTK) pathways can lead to diﬀerent cellular responses and signaling
outcomes. Also, the presence of target eﬀectors and the timing of their activation are important in determining cell fate
decisions towards proliferation or diﬀerentiation [11].
During muscle diﬀerentiation, MAPK signals play an
important role [12]. Marshall reported that a prolonged activation of ERK1/2 leads to diﬀerentiation, whereas a transient
activation of ERK1/2 leads to proliferation, as it is not suﬃcient to elevate the levels of nuclear ERK1/2 [13]. Therefore,
the availability of growth factors in the microenvironment

and the receptors they activate determine stem cell fate
through the signaling intermediates activated. Furthermore,
it is known that IGFs mediate and induce myogenesis by
directly activating the myogenin gene promoter. However,
when the PI3K inhibitor, LY294002, which acts upstream of
AKT signaling, is introduced, IGF is no longer able to induce
myogenesis or enhance the expression of myogenin [14].
Therefore, the direct eﬀects of the IGF stimulation on the
myogenin promoter are also mediated via the actions of
PI3K via AKT signaling. Additionally, IGF-1R signaling
through PI3K was shown to upregulate myogenin expression
leading to an enhanced myogenesis [14] and also regulate
basal levels of IGF-1 and IGF-2 genes during myogenesis
[14, 15]. C2BP5 myoblast diﬀerentiation was still achieved
when transfected by recombinant adenoviruses expressing
MyoD in the absence of IGFs [16]. When MyoD-transfected
C2BP5 cells were treated with LY294002, the transcriptional
activity of MyoD, Myogenin, and MHC was not inhibited
but the myoﬁbers were smaller and thinner with fewer nuclei
[16]. Collectively, these studies suggested that IGF-activated
PI3K-AKT and MAPK pathways are both important for
myoblast diﬀerentiation [17].
IGFs interact with insulin for metabolism, survival,
proliferation, and diﬀerentiation of many cell types either
through IGF-1R or the insulin receptor (IR) or the IGF1R-IR hybrid receptor [18–20]. Both the IGF-1R and IR are
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Figure 2: PMSCs treated with IGF-1R inhibitor (PPP) showed reduced p-AKT and p-ERK1/2 levels that were reversed by IGFBP-6 addition.
(a, b) PMSCs treated with PPP showed lower protein levels of p-AKT p-ERK1/2 at the later time points when compared to the PMSCs under
muscle diﬀerentiation conditions alone. When IGFBP-6 was added to PPP, p-AKT and p-ERK1/2 levels increased at all time points compared
to PPP alone. Protein levels were quantiﬁed by densitometry and normalized to total AKT or total ERK1/2. Data is presented as the
mean ± SEM of 3 independent experiments from one preterm placenta. Two-way ANOVA with Bonferroni’s multiple comparison
test was performed to determine ∗ P < 0 05, ∗∗ P < 0 01, and ∗∗∗ P < 0 001 compared to muscle diﬀerentiation conditions or # P < 0 05 and
###
P < 0 001 compared to PPP.

tyrosine protein kinases that activate multiple signaling
transduction pathways [20, 21]. The PI3K-AKT pathway
but not the MAPK is activated by insulin [21]. It is known
that each ligand binds to its respective receptor with higher
aﬃnity and to the other receptor or hybrid receptors with
lower aﬃnity. While IGFs play a major role in cellular proliferation, diﬀerentiation, and survival, and insulin has a major
role in metabolism, their functions are interchangeable
depending on the concentration of the peptide in the extracellular space.
Circulating IGFs are bound to six soluble IGF-binding
proteins (IGFBPs 1–6), which determine the bioavailability
of free IGFs in the extracellular environment, thus modifying
the IGF actions [22]. Under normal physiological conditions,
IGFs bind IGFBPs with greater aﬃnity than they bind IGF1R, playing an important role in IGF-regulated cell metabolism, development, and growth. In addition, it has become
apparent that the IGFBPs can be expressed and maintained
within the cellular microenvironment and have additional
functions independent of regulating IGFs [22].
In RD rhabdomyosarcoma and LIM 1215 colon cancer
cells, mutant IGFBP-6 that does not bind to IGF-2 induces
cellular migration, suggesting an IGF-independent function
of IGFBP-6 [23]. Inhibition of ERK1/2 but not AKT impeded
cellular migration [23]. We have previously reported that
IGFBP-6, which has high aﬃnity to IGF-2 [24, 25], stimulates
a multipotent proﬁle and an early commitment to the muscle
lineage in PMSCs [26]. Furthermore, the impact of extracellular IGFBP-6 and silencing of endogenous IGFBP-6 suggest

that the biologic actions of IGFBP-6 occur in both IGFdependent and IGF-independent mechanisms [19, 27–29].
The mechanisms of IGF-dependent and IGF-independent
actions are not yet delineated. In this study, we demonstrated
that the biologic actions of IGFBP-6 on PMSC diﬀerentiation
into the skeletal muscle occur independently of either IGFs or
insulin signaling through IGF-1R or IR.

2. Materials and Methods
2.1. Isolation of PMSCs. PMSC isolation and experiments
were conducted in accordance with the approval from the
Health Sciences Research Ethics Board of Western University. Informed consent was obtained from healthy women
undergoing therapeutic termination of pregnancy, and the
PMSCs used in this study were isolated from 15 weeks preterm placental tissues. After surgery, chorionic villi were
dissected, washed, minced with surgical scissors and forceps, and subjected to enzymatic digestion with collagenase
IV (369 IU/mg), hyaluronidase (999 IU/mg) (SigmaAldrich), and DNase I (2,000 IU/mg) (Hoﬀmann-La Roche)
for 10 minutes at room temperature, followed by 0.05%
trypsin (Gibco/Invitrogen) for 5 minutes at room temperature. The sample was then washed for 10 minutes with
10% FBS in DMEM/F12, and the resulting single cell suspension was separated by density centrifugation over a
Percoll gradient using a modiﬁed protocol by Worton
et al. [26, 30].
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Figure 3: PMSCs treated with PPP showed increased IGFBP-6 secretion but decreased IGF-2 secretion. (a) IGFBP-6 secretion was increased
after PPP treatment at all time points compared to muscle diﬀerentiation conditions alone. (b) IGF-2 secretion was reduced at 3 and 7 days
compared to muscle diﬀerentiation conditions alone. IGFBP-6 with PPP did not have an additional eﬀect. Data is presented as the mean
± SEM of 3 independent experiments from one preterm placenta. Two-way ANOVA with Bonferroni’s multiple comparison test was
performed to determine ∗ P < 0 05, ∗∗ P < 0 01, and ∗∗∗ P < 0 001 compared to muscle diﬀerentiation conditions alone.
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Figure 4: PMSCs treated with LY294002 reduced diﬀerentiated muscle compaction at 7 and 14 days, while IGFBP-6 with LY294002 delayed
muscle compaction changes to 14 days. Higher magniﬁcation of PMSCs treated with LY294002 or with IGFBP-6 supplementation with
LY294002. PMSCs treated with LY294002, a PI3K inhibitor upstream of AKT, under muscle diﬀerentiation conditions showed less
skeletal muscle compaction at 7 days compared to muscle diﬀerentiation alone, but the addition of IGFBP-6 with LY294002 delayed these
changes (more compaction) as seen with the white arrows compared to the inhibitor alone (20x). Images are representative of 3
independent experiments from one preterm placenta.

2.2. Muscle Diﬀerentiation and Treatments. Cells were plated
in muscle growth media (fetal bovine serum 0.05 mL/mL,
fetuin 50 μg/mL, epidermal growth factor 10 ng/mL, basic
ﬁbroblast growth factor 1 ng/mL, insulin 10 μg/mL, and
dexamethasone 0.4 μg/mL) for 48 hours before changing
to skeletal muscle diﬀerentiation media, which is a proprietary serum-free medium containing 10 μg/mL insulin (PromoCell) for 14 days. PMSCs were treated every 3 days with
200 nM of IGF-IR inhibitor PPP, 25 μM of AKT inhibitor
LY294002, 10 μM of MEK1/2 inhibitor U0126, or 10 μM
of IR inhibitor HNMPA (Santa Cruz Biotechnology) under
muscle diﬀerentiation conditions. Treatment concentrations for LY294002, U0126, and HNMPA were determined
by a dose-response experiment using PMSCs in muscle differentiation media (Supplementary Figure 1). For IGFBP-6
supplementation with the inhibitors, recombinant human

IGFBP-6 (ProSpec) was added to the media (375 ng/mL)
every 3 days at the time of media change. The dose of
IGFBP-6 was based on our previous studies [26, 31].
2.3. Immunoblotting. Cell lysates containing 20 μg of
protein were added to 6x SDS gel loading buﬀer. Samples
were resolved by molecular weight using 10% SDSpolyacrylamide gels transferred onto polyvinylidene ﬂuoride (PVDF) membranes using Trans-Blot Turbo (Bio-Rad)
with an optimized protocol depending on protein size.
Membranes were blocked with 5% nonfat dry milk, gently
shaking for 1 hour at room temperature in Tris-HCl buﬀer
saline pH 8.0 with 0.1% Tween-20 (TBS-T). Blots were
washed with TBS-T followed by incubation at 4°C overnight with speciﬁc primary antibodies in 5% BSA or 5%
nonfat dry milk in TBS-T following the manufacturer’s
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⁎
###

Stem Cells International

7

Muscle diﬀ. +IGFBP-6 + LY294002 +LY & IGFBP-6
1 3 7 14 1 3 7 14 1 3 7 14 1 3 7 14
57 kDa
Pax3/7
훽-Actin

43 kDa

Pax3/7 levels (arbitrary units)

Pax3/7
⁎⁎⁎

3
2

⁎⁎⁎

1

⁎⁎⁎
@
#

⁎⁎⁎
###

⁎⁎⁎ ⁎⁎⁎
@
###

⁎⁎⁎
⁎⁎⁎

@@@

@@@

@@@

@@@ @@@

0
1

3

7

14

Days
Muscle diﬀerentiation
Muscle diﬀerentiation (+BP6)
MD (+LY294002)
MD (+LY and IGFBP-6)

(g)

Figure 5: LY294002 treatment reduced IGFBP-6 and potency-associated and muscle diﬀerentiation markers. (a) IGFBP-6 protein levels
decreased with LY294002 at days 1 and 14 as compared to muscle diﬀerentiation alone, and adding extracellular IGFBP-6 with the
treatment did not cause additional changes to IGFBP-6 levels. (b, c) PMSCs treated with LY294002 decreased OCT4 (at day 1) and SOX2
(at each time point) compared to muscle diﬀerentiation, whereas IGFBP-6 addition with LY294002 increased OCT4 expression at 3, 7,
and 14 days and at day 14 for SOX2 compared to LY294002 alone. Muscle lineage diﬀerentiation marker protein levels were reduced with
LY294002 for (d) MyoD from 3 to 14 days, (e) MyoG at 7 and 14 days, and (f) MHC at all time points. IGFBP-6 supplementation with
LY294002 increased MyoD levels at 1 and 3 days and MHC levels at 3, 7, and 14 days compared to LY294002 treatment. (g) Pax3/7
protein levels decreased with LY294002 at day 7. IGFBP-6 addition with the inhibitor increased Pax3/7 levels until day 7. Protein levels
were quantiﬁed by densitometry and normalized to β-actin. Data is presented as the mean ± SEM of 3 independent experiments from one
preterm placenta. Two-way ANOVA with Bonferroni’s multiple comparison test was performed to determine ∗ P < 0 05, ∗∗ P < 0 01,
and ∗∗∗ P < 0 001 compared to muscle diﬀerentiation conditions # P < 0 05, ## P < 0 01, and ### P < 0 001 compared to LY294002, or
P < 0 001 compared to muscle diﬀerentiation with IGFBP-6.

protocol. To detect markers of cell potency, antibodies for
OCT4 antibody (Santa Cruz Biotechnology) and SOX2
(Epitomics) were used. To detect the markers of muscle differentiation, Pax3/7, MyoD, Myogenin, and Myosin heavy
chain (Santa Cruz Biotechnology) were used. To detect
the activated signaling molecules, we used phospho-p44/42
MAPK, p44/42 MAPK, phospho-AKT, and AKT (Cell Signaling Technology). Then membranes were washed and
incubated at room temperature with the corresponding secondary HRP-conjugated antibody. Resolved protein bands
were detected using chemiluminescence, and images were
taken using the VersaDoc Imager (Bio-Rad) [25, 30].
2.4. Quantiﬁcation of IGFBP-6 and IGF-2 by Enzyme-Linked
Immunosorbent Assay (ELISA). Human IGFBP-6 (RayBiotech®) and IGF-2 (ALPCO) ELISA kits were used to measure
the amount of IGFBP-6 and IGF-2 secreted into PMSCconditioned media. Standards and samples were loaded into
the wells, and the immobilized antibody bound the IGFBP-6
or IGF-2 present in the sample. The wells were washed and
biotinylated anti-human antibody was added. After washing,
HRP-conjugated streptavidin was added; then, a TMB substrate solution was used to develop a blue color in proportion
to the amount of IGFBP-6 or IGF-2 bound. The stop solution
changes color from blue to yellow, and the intensity was measured at 450 nm using the Multiskan Ascent plate reader and
analysis software [26, 31].

2.5. Aldehyde Dehydrogenase (ALDH) Activity. ALDH activity, a conserved progenitor cell function, was assessed by ﬂow
cytometry at days 1, 3, 7, and 14 using the Aldeﬂuor™ assay
(STEMCELL Technologies), as per the manufacturer’s
instructions. Brieﬂy, 5 μL of activated Aldeﬂuor reagent was
added to 1 mL of cell suspension and incubated for 45
minutes at 37°C. Cells were washed and resuspended in
500 μL of ice-cold Aldeﬂuor assay buﬀer, and ALDH activity
was measured using ﬂow cytometry. As a negative control,
Aldeﬂuor™ DEAB reagent was used [26, 31].
2.6. Statistical Analysis. All experiments were performed in
triplicate from one 15-week placental tissue (technical replicates). GraphPad Prism Software 5.0 was used to generate
all graphs and analyses. A two-way ANOVA followed by
Bonferroni’s multiple comparison test or a one-way ANOVA
followed by Student’s t-test was used to calculate signiﬁcant
diﬀerences when P < 0 05. Graphic representation values
are presented as mean ± SEM (shown as variance bars).

3. Results
3.1. IGF-1R and IGFBP-6 Are Required for PMSC
Diﬀerentiation into the Skeletal Muscle. To evaluate the
eﬀects of IGF-1R inhibition on potency-associated and
muscle diﬀerentiation markers in PMSCs under muscle
diﬀerentiation conditions, PPP (IGF-1R-speciﬁc autophosphorylation inhibitor) was used during PMSC muscle
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3.2. IGFBP-6 Is Required for PMSC Muscle Diﬀerentiation
after Inhibition of the PI3K Pathway. To better understand
downstream signaling of the IGF-1R, LY294002 was used
to inhibit PI3K signaling pathway. LY294002 alone reduced
diﬀerentiated muscle morphology at 7 days (Figure 4 and
Supplementary Figure 2). However, the addition of IGFBP6 with LY294002 delayed these changes until day 14
postdiﬀerentiation (Figure 4 and Supplementary Figure 2).
Using immunoblotting, IGFBP-6 expression was decreased

ALDH+
30
Percentage of cells (%)

diﬀerentiation for 14 days with/without IGFBP-6 supplementation every 3 days. As determined by immunoblotting,
the presence of PPP decreased IGFBP-6 protein levels at 14
days (Figure 1(a)). Potency-associated marker (OCT4 and
SOX2) levels were decreased by PPP treatment compared to
muscle diﬀerentiation alone (Figures 1(b) and 1(c)). The
muscle commitment marker Pax3/7 levels were decreased
by PPP treatment at 7 and 14 days (Figure 1(d)). Similarly,
the protein levels of the muscle lineage diﬀerentiation
markers MyoD and MyoG were decreased at 7 and 14 days
(Figures 1(e) and 1(f)). In contrast, MHC levels were reduced
at all time points after PPP treatment compared to muscle
diﬀerentiation (Figure 1(g)). Overall, PPP treatment signiﬁcantly delayed muscle lineage commitment and diﬀerentiation in vitro.
To determine whether IGFBP-6 could rescue PMSC
diﬀerentiation into the skeletal muscle during IGF-1R inhibition, extracellular IGFBP-6 was added to the culture alongside PPP supplementation. As predicted, IGFBP-6 levels
increased after coadministration of IGFBP-6 with PPP at
day 14 compared to the inhibitor alone (Figure 1(a)). Also,
OCT4 protein levels were increased at 14 days with the
combined treatments, while SOX2 levels were not changed
compared to the inhibitor alone (Figures 1(b) and 1(c)). Furthermore, IGFBP-6 supplementation with PPP increased the
levels of the muscle lineage diﬀerentiation markers Pax3/7,
MyoD, MyoG, and MHC from 3 to 14 days compared to
PPP alone (Figures 1(d)–1(g)). Moreover, the addition of
IGFBP-6 alone without PPP was tested, and there were no signiﬁcant changes compared to the addition of IGFBP-6 with
PPP (data not shown). These ﬁndings indicate that IGFBP6 may be an important regulator of skeletal muscle diﬀerentiation and its action, in part, occurred without activating
IGF-1R signaling and independent of IGF.
Downstream of the IGF-1R signaling, the presence of
PPP during muscle diﬀerentiation caused a reduction in
p-AKT levels at 7 days which was signiﬁcant by day 14 and
in p-ERK1/2 levels at 7 and 14 days when compared to muscle diﬀerentiation alone (Figures 2(a) and 2(b)). In contrast,
IGFBP-6 increased both p-AKT and p-ERK1/2 protein levels
at all time points in the presence of PPP under muscle diﬀerentiation conditions compared to PPP alone indicating that
IGFBP-6 may trigger MAPK signal transduction cascade
independent of IGFs (Figures 2(a) and 2(b)). In the presence
of PPP, IGFBP-6 secretion into the conditioned media was
increased compared to muscle diﬀerentiation (Figure 3(a)),
whereas IGF-2 secretion was reduced at days 3 and 7
(Figures 3(b)); these eﬀects could be because the exogenously
added IGFBP-6 is internalized (data not shown).

Stem Cells International

20

⁎⁎⁎

10

⁎⁎⁎
##

###
⁎⁎⁎
⁎⁎⁎ ⁎

0
1

3

7

14

Days
Muscle diﬀerentiation
MD (+LY294002)
MD (+LY and IGFBP-6)

Figure 6: PMSCs treated with LY294002 and LY294002 with
IGFBP-6 under skeletal muscle diﬀerentiation conditions decreased
the frequency of cells with high ALDH activity. Compared to the
PMSCs under muscle diﬀerentiation conditions, cells treated with
LY294002 showed a decreased frequency of cells with high ALDH
activity at 1, 3, and 7 days. IGFBP-6 with LY294002 treatment
decreased frequency of cells with high ALDH activity only at day 1
and a signiﬁcantly increased ALDH+ cells at day 3 compared to
LY294002 treatment alone. Data is presented as the mean ± SEM of
3 independent experiments from one preterm placenta. Two-way
ANOVA with Bonferroni’s multiple comparison test was
performed to determine ∗ P < 0 05 and ∗∗∗ P < 0 001 compared to
muscle diﬀerentiation or ## P < 0 01 and ### P < 0 001 compared to
LY294002 alone.

at days 1 and 14 in the presence of LY294002 and remained
decreased despite IGFBP-6 supplementation (Figure 5(a)).
Furthermore, LY294002 treatment reduced the protein levels
of the potency-associated markers OCT4 (Figure 5(b)) at day
1 and SOX2 (Figure 5(c)) at all time points as compared to
muscle diﬀerentiation alone. After IGFBP-6 supplementation
with LY294002 treatment, OCT4 levels were maintained
higher at all time points, while SOX2 expression was higher
at day 14 compared to LY294002 treatment alone
(Figures 5(b) and 5(c)). The levels of the muscle lineage
markers MyoD, MyoG, and MHC decreased with LY294002
treatment as compared with muscle diﬀerentiation alone
(Figures 5(d)–5(f)). IGFBP-6 addition with LY294002
treatment increased MyoD protein levels at days 1 and 3
(Figure 5(d)), while MHC levels were increased compared to
LY294002 treatment alone (Figure 5(f)). These results
indicated that muscle commitment occurred earlier in the
presence of IGFBP-6 with LY294002 treatment. To conﬁrm
this hypothesis, Pax3/7, the muscle commitment marker,
expression was tested. Pax3/7 protein levels were increased
after IGFBP-6 addition with LY294002 (Figure 5(g)),
suggesting an earlier commitment to the muscle lineage
when IGFBP-6 was present.
We used the Aldeﬂuor™ assay to determine the frequency of progenitor cells with high ALDH activity, a more
primitive progenitor phenotype. Compared to PMSCs under
muscle diﬀerentiation alone, there was a decrease in the frequency of cells with high ALDH activity (ALDH+ cells) in
PMSCs treated with LY294002 until day 7 (Figure 6 and
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Figure 7: PMSCs treated with U0126 under muscle diﬀerentiation conditions showed reduced muscle compaction at 3 days. PMSCs under
muscle diﬀerentiation conditions with U0126, a MEK inhibitor upstream of ERK1/2, showed less skeletal muscle diﬀerentiation at 3, 7, and 14
days with a change in cell morphology at 14 days compared to muscle diﬀerentiation (10x). The images are the representative of 3
independent experiments from one preterm placenta.

Supplementary Figure 3). Moreover, IGFBP-6 with LY294002
treatment reduced the frequency of cells with high ALDH
activity at day 1 but was maintained at a higher number
compared to LY294002 alone at day 3. Thus, IGFBP-6
prolonged the progenitor phenotype in PMSCs when the
PI3K pathway is inhibited under muscle diﬀerentiation
conditions. These results show that the PI3K pathway is
essential for muscle diﬀerentiation, and when the pathway
was inhibited, IGFBP-6 could overcome the impact by
allowing the cells to commit earlier to the muscle lineage and
enhancing late-stage diﬀerentiation.
3.3. MAPK Signaling Is Required for PMSC Diﬀerentiation
into the Skeletal Muscle. To test the downstream signaling
of the IGF-1R via the MAPK pathway, U0126 was used to
inhibit MAPK signaling, which phosphorylates ERK1/2.
PMSCs treated with U0126 under muscle diﬀerentiation
conditions showed reduced muscle cell compaction from 3
to 14 days with a change in muscle morphology compared
to the PMSCs under muscle diﬀerentiation alone. IGFBP-6
supplementation with U0126 treatment showed similar morphology to U0126 alone (Figure 7). Using immunoblotting,
IGFBP-6 levels were reduced with U0126 treatment and adding IGFBP-6 did not increase IGFBP-6 levels, indicating that

MAPK is an important pathway for IGFBP-6 production
(Figure 8(a)). OCT4 levels were reduced at day 1 by U0126
alone or U0126 with IGFBP-6 addition; however, U0126 with
IGFBP-6 treatment maintained higher levels of OCT4 at 7
and 14 days until a signiﬁcant decrease at day 14 compared
to U0126 alone (Figure 8(b)). In contrast, potencyassociated marker SOX2 protein levels were decreased by
U0126 until 7 days and were increased by IGFBP-6 at 7
and 14 days compared to U0126 alone (Figure 8(c)). The protein levels of the early and late muscle lineage diﬀerentiation
markers MyoD, MyoG, and MHC were signiﬁcantly reduced
after day 3 with U0126, and adding IGFBP-6 with U0126 did
not reverse these eﬀects (Figures 8(d)–8(f)). These ﬁndings
suggest that MAPK is a critical pathway for PMSC skeletal
muscle diﬀerentiation and cannot be substituted by an alternative pathway. The fact that IGFBP-6 did not accumulate in
the intracellular environment when MAPK was inhibited
shows that the MAPK pathway may be important for
IGFBP-6 action on PMSC diﬀerentiation; however, this is
not the only possible explanation, and it could be due to other
eﬀects caused by the MAPK inhibition or because the
IGF-1R-dependent pathway is involved. PMSCs treated with
U0126 under muscle diﬀerentiation conditions decreased the
frequency of cells with high ALDH activity compared to the
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Figure 8: Continued.

Stem Cells International

11
Muscle diﬀ

(+) U0126

(+) U0126 & IGFBP-6

1d 3d 7d 14d 1d 3d 7d 14d 1d 3d 7d 14d
200 kDa

MHC
훽-Actin

43 kDa
MHC

MHC levels (arbitrary units)

0.15

0.10

0.05
⁎⁎⁎ ⁎⁎⁎

⁎⁎ ⁎⁎

⁎⁎⁎ ⁎⁎⁎

0.00
1

3

7

14

Days
Muscle diﬀerentiation
MD (+U0126)
MD (+U0126 and IGFBP-6)

(f)

Figure 8: PMSCs treated with U0126 under muscle diﬀerentiation conditions reduced protein levels of IGFBP-6 and potency-associated and
muscle diﬀerentiation markers. (a) U0126 decreased IGFBP-6 protein levels and adding IGFBP-6 with U0126 did not cause additional
changes to IGFBP-6 levels. (b) Potency-associated marker OCT4 protein levels reduced with U0126 treatment at day 1with increased
levels at 7 days. IGFBP-6 addition with U0126 increased OCT4 levels at 3 and 7 days compared to U0126 treatment alone. (c) SOX2
protein levels were lower at 1, 3, and 7 days compared to muscle diﬀerentiation. IGFBP-6 addition with U0126 decreased SOX2 levels at
day 1 with an increase at 7 and 14 days compared to U0126. (d–f) Protein levels of the muscle diﬀerentiation markers MyoD, MyoG, and
MHC were decreased at the later time points with U0126 and adding IGFBP-6 with U0126 did not change these eﬀects. Protein levels
were quantiﬁed by densitometry and normalized to β-actin. Data is presented as the mean ± SEM of 3 independent experiments from one
preterm placenta. Two-way ANOVA with Bonferroni’s multiple comparison test was performed to determine ∗ P < 0 05, ∗∗ P < 0 01, and
∗∗∗
P < 0 001 compared to muscle diﬀerentiation or # P < 0 05, ## P < 0 01, and ### P < 0 001 compared to U0126.

3.4. Inhibition of Insulin Receptor Signaling Delayed PMSC
Diﬀerentiation into the Skeletal Muscle and Adding IGFBP-6
Rescued the Eﬀects. To test the role of insulin receptor (IR)
signaling in the diﬀerentiation of PMSCs into the skeletal
muscle, HNMPA was used to block IR kinase activity as
it is speciﬁc for the IR and does not aﬀect the IGF-1R.
Neither HNMPA nor HNMPA with IGFBP-6 impacted
diﬀerentiated cell morphology when compared to muscle
diﬀerentiation conditions alone. However, HNMPA treatment delayed muscle diﬀerentiation (less compaction) at
day 14, compared to control treatment (Figure 10 and
Supplementary Figure 5).
Intracellular IGFBP-6 levels were unchanged by HNMPA
except for a reduction at day 7; however, adding IGFBP-6
with HNMPA increased IGFBP-6 protein levels at 3, 7, and
14 days (Figure 11(a)). HNPMA did not change the protein

ALDH+
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PMSCs under untreated muscle diﬀerentiation condition at
1, 3, and 7 days (Figure 9 and Supplementary Figure 4). In
contrast, adding IGFBP-6 with U0126 treatment increased
the frequency of cells with high ALDH activity compared
to the PMSCs treated with U0126 alone. Therefore, in
PMSCs under muscle diﬀerentiation conditions, IGFBP-6
acts in an IGF-1R-dependent manner mainly through the
MAPK pathway.
Consequently, triggering downstream phosphorylation
of AKT or ERK1/2 independent of IGF-1R activation by
IGFBP-6 via an unknown mechanism could be responsible
for IGFBP-6 impact on muscle cell diﬀerentiation.
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Figure 9: PMSCs treated with U0126 and U0126 with IGFBP-6
under skeletal muscle diﬀerentiation conditions decreased the
frequency of cells with high ALDH activity. U0126 treatment
showed decreased frequency of cells with high ALDH activity at 1,
3, and 7 days compared to muscle diﬀerentiation alone. IGFBP-6
supplementation with U0126 increased frequency of cells with
high ALDH activity at 1, 3, and 7 days compared to U0126. Data
is presented as the mean ± SEM of 3 independent experiments
from one preterm placenta. Two-way ANOVA with Bonferroni’s
multiple comparison test was performed to determine ∗ P < 0 05
and ∗∗∗ P < 0 001 compared to muscle diﬀerentiation or ## P < 0 01
and ### P < 0 001 compared to U0126.
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Figure 10: PMSCs under muscle diﬀerentiation conditions treated with HNMPA show delayed muscle compaction at 14 days. PMSCs under
muscle diﬀerentiation conditions, with HNMPA or HNMPA with extracellular IGFBP-6, showed minimal change in skeletal muscle
morphology and density at day 14 when compared to muscle diﬀerentiation (10x). The images are the representative of 3 independent
experiments from one preterm placenta.

levels of the potency-associated markers (OCT4 and SOX2)
but addition of extracellular IGFBP-6 with HNMPA
increased both markers at days 7 and 14 compared to the
PMSCs under muscle diﬀerentiation conditions and PMSCs
treated with HNMPA (Figures 11(b) and 11(c)). Additionally, the levels of the muscle lineage diﬀerentiation markers
MyoD, MyoG, and MHC were decreased at the later time
points with HNMPA compared to PMSCs under muscle differentiation conditions, and extracellular IGFBP-6 increased
MyoG and MHC levels at 7 and 14 days compared to
HNMPA alone (Figures 11(d)–11(f)). These results suggest
that insulin or IGFs could trigger myogenic diﬀerentiation;
however, IGFBP-6 could also promote diﬀerentiation independent of insulin or IGFs.

4. Discussion
The promise of using stem cells in treating diseases is
becoming closer to be used in the clinic [32, 33]. Still,

understanding the niche factors and their inﬂuence on stem
cell proliferation and diﬀerentiation in vitro is essential
before stem cells can be used safely in regenerative medicine
applications [34]. Muscle diﬀerentiation is a multistep process, starting with commitment to the muscle lineage and
ending with the formation of multinucleated myotubes [2].
The IGF family is an essential early niche factor for stem cell
survival, growth, proliferation, and diﬀerentiation [24]. It is
also important in the skeletal muscle niche, with a major
role in muscle development [5, 6, 9]. IGFBP-6 is expressed
in the developing cells [23, 26–28]. We have demonstrated
that the balance between intracellular and extracellular
IGFBP-6 levels is required for modulating muscle diﬀerentiation by PMSCs [26] and that the eﬀects of IGFBP-6 on
muscle diﬀerentiation are both IGF-dependent and IGFindependent [31]. These ﬁndings provided basic insight into
the role of IGFBP-6 and IGFs on PMSC muscle diﬀerentiation. The aim of this study was to characterize the eﬀects
of IGF-1R and IR activation on the diﬀerentiation of
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Figure 11: PMSCs treated with HNMPA under muscle diﬀerentiation conditions reduced muscle diﬀerentiation markers with no change in
potency-associated markers. (a) HNMPA treatment decreased IGFBP-6 protein levels at 7 days as compared to muscle diﬀerentiation.
IGFBP-6 supplementation with HNMPA increased IGFBP-6 levels at 3, 7, and 14 days. (b, c) HNMPA treatment did not change the
protein levels of the pluripotency-associated markers OCT4 and SOX2. IGFBP-6 with HNMPA treatment increased the levels at 7 and
14 days. (d–f) HNMPA treatment decreased the protein levels of the muscle lineage diﬀerentiation markers MyoD, MyoG, and MHC
at the later time points (3-14 days). IGFBP-6 addition with HNMPA treatment increased MyoG and MHC levels at 7 and 14 days
compared to HNMPA treatment alone. Protein levels were quantiﬁed by densitometry and normalized to β-actin. Data is presented as
the mean ± SEM of 3 independent experiments from one preterm placenta. Two-way ANOVA with Bonferroni’s multiple comparison
test was performed to determine ∗ P < 0 05, ∗∗ P < 0 01, and ∗∗∗ P < 0 001 compared to muscle diﬀerentiation conditions or # P < 0 05,
##
P < 0 01, and ### P < 0 001 compared to HNMPA.

PMSCs into skeletal muscle and to investigate IGFBP-6
role in this process.
In these studies, we demonstrated that IGF-1R and its
downstream signaling pathways (PI3K-AKT and MAPK
pathways) were required for PMSC muscle diﬀerentiation.
We also showed that when the PI3K pathway was inhibited,
increased extracellular IGFBP-6 improved PMSC diﬀerentiation into the skeletal muscle as seen with the increased protein levels of MyoD and MHC. In contrast, MAPK pathway
inhibition could not be rescued by increased extracellular
IGFBP-6 as seen with the unchanged protein levels of the
muscle lineage diﬀerentiation markers. MAPK inhibition
also caused a signiﬁcant decrease in intracellular IGFBP-6
concentrations, which could not be reversed by the addition
of extracellular IGFBP-6 as seen with the unaﬀected IGF
BP-6 protein levels. These studies suggested that MAPK signaling is an important pathway for PMSC diﬀerentiation into
the skeletal muscle and that intracellular IGFBP-6 compliments this process. Therefore, we suggest that in PMSCs,
IGFBP-6 acts in an IGF-1R-dependent manner predominantly through the MAPK signaling pathway and not
through PI3K to achieve skeletal muscle diﬀerentiation. We
further veriﬁed the importance of the insulin receptor (IR)
in PMSC diﬀerentiation into the muscle and the interaction
with IGFBP-6.

We demonstrated that IR plays an important role in
PMSC muscle diﬀerentiation in addition to IGF-1R. We
showed that inhibiting IR signaling delayed PMSC diﬀerentiation into the skeletal muscle but did not completely block
the process as IGF-1R signaling was still active and most
likely mediated the diﬀerentiation process. These observations also suggested that the induction of muscle diﬀerentiation by the high concentration of insulin (10 μg/mL) in the
media is likely exerted by insulin binding to the IGF-1R, to
which it has low-aﬃnity binding capacity. The fact that
IGFBP-6 enhanced muscle diﬀerentiation when IR was
inhibited suggests that IGFBP-6-induced PMSC diﬀerentiation into the muscle could occur independent of IR signaling.
The IGF-1R and IR are both receptor tyrosine kinases
that activate several signaling transduction pathways
[20, 21]. IGFs and insulin both promote cell proliferation
and diﬀerentiation [10, 18–20], and IGFs also possess
insulin-like metabolic eﬀects, including increased glucose
uptake in the skeletal muscle, mediated by either IGF-1R or
IR [35]. Previous reports show that high concentrations of
insulin activates both IGF-1R and IR [36, 37]; however, not
much attention is given to IGF-1R binding aﬃnity and eﬀects
versus IR when insulin is used.
Therefore, in future studies, a phosphokinase array may
be used to specify interacting adaptors and signaling proteins
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inhibited in vitro, IGFBP-6 addition enhanced the muscle diﬀerentiation process of PMSCs with MAPK being a critical pathway for this
diﬀerentiation process.
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within complementary IGF-1R and IR signaling pathways.
Also, alterations in the PMSC microenvironment can cause
epigenetic changes, and it will be interesting to understand
whether the IGF system aﬀects potency and myogenesis
through epigenetic modulation of promoter regions.
These results are in agreement with previous reports
on the importance of IGF-1R and its downstream pathways and the IR in muscle development and diﬀerentiation. However, this study is the ﬁrst to show these
eﬀects on human stem cells isolated from the placenta
and that IGFBP-6 addition enhanced the muscle diﬀerentiation process of PMSCs when IGF-1R or IR were inhibited in vitro.
Diﬀerent signaling pathways, including IGF-1R and IR,
crosstalk, and the complexity of signaling and its eﬀects on
PMSC diﬀerentiation into the muscle are beyond the scope
of one study. The possibility that a diﬀerent pathway, not
examined in this study, is responsible for IGFBP-6 eﬀects
on PMSC diﬀerentiation into the skeletal muscle must be
considered and further investigated to better understand
the IGFBP-6 role in this diﬀerentiation process. Moreover,
to conﬁrm the results from this study, increasing the sample
number to have biological replicates is vital as experiments
were performed from one preterm placental tissue (15
weeks). Therefore, future studies are warranted to directly
compare MSCs from the chorionic villi of diﬀerent gestations
(preterm and full-term human placentae), which will further
improve our understanding of skeletal muscle diﬀerentiation
and the eﬀects of the IGF system based on ontogeny, and will
help in choosing the best gestation age PMSC for skeletal
muscle diﬀerentiation.
To date, previous studies on the role of the IGF family,
speciﬁcally IGFBP-6, have not been reported during the differentiation of PMSCs towards the skeletal muscle lineage.
Therefore, data presented in this study provides insight into
the mechanisms of diﬀerentiation from PMSCs into the skeletal muscle by IGFs and IGFBP-6 during development and
suggests that both the IGF-1R and IR signaling are important
signaling pathways in PMSC diﬀerentiation towards skeletal
muscle lineage. In addition, IGFBP-6 is also important for
diﬀerentiation to occur, due to a combination of IGFdependent and IGF-independent functions (Figure 12).
Overall, manipulating the PMSC microenvironment using
the IGF system, particularly IGFBP-6, can improve PMSC
myogenic diﬀerentiation, a ﬁrst step towards PMSC use for
muscle regeneration therapies.
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Supplementary Materials
Supplementary Figure 1: PMSCs under muscle diﬀerentiation conditions treated with diﬀerent concentrations of
PI3K, MAPK, and IR inhibitors. Cells were treated with different concentrations of (A) LY294002 (PI3K inhibitor), (B)
U0126 (MAPK inhibitor), or (C) HNMAP (insulin receptor
inhibitor) for 3 days under muscle diﬀerentiation conditions
to assess the optimal concentration to be used. The concentration of the inhibitors was selected based on maintaining
low band intensity for the duration of the experiment (3
days) compared to muscle diﬀerentiation alone. 25 μM of
the AKT inhibitor LY294002, 10 μM of the ERK1/2 inhibitor
U0126, and 10 μM of the IR inhibitor HNMPA were selected.
Protein levels were quantiﬁed by densitometry and normalized to total AKT, total ERK1/2, or β-actin. Data is presented
as the mean ± SEM of 3 independent experiments from one
preterm placenta. Two-way ANOVA with Bonferroni’s multiple comparison test was performed to determine ∗ P < 0 05,
∗∗
P < 0 01, and ∗∗∗ P < 0 001 compared to muscle diﬀerentiation conditions. Supplementary Figure 2: PMSCs treated
with LY294002, a PI3K inhibitor upstream of AKT, under
muscle diﬀerentiation conditions showed less skeletal muscle
morphology at 7 and 14 days, but the addition of IGFBP-6
with LY294002 delayed these changes until day 14 (10x).
The images are the representative of 3 independent experiments from one preterm placenta. Supplementary Figure 3:
representative ﬂow cytometry dot plots showing the frequency of PMSCs with high ALDH activity when cultured
under muscle diﬀerentiation conditions with or without
LY294002 or LY294002 and IGFBP-6 at (A) day 1, (B) day
3, (C) day 7, and (D) day 14. DEAB-treated controls were
used to establish the ALDH gate (data not shown). Supplementary Figure 4: representative ﬂow cytometry dot plots
showing the frequency of PMSCs with high ALDH activity
when cultured under muscle diﬀerentiation conditions with
or without either U0126 or U0126 and extracellular
IGFBP-6 at (A) day 1, (B) day 3, (C) day 7, and (D) day 14.
DEAB-treated controls were used to establish the ALDH gate
(data not shown). Supplementary Figure 5: higher magniﬁcation of PMSCs treated with HNMPA or with IGFBP-6 supplementation with HNMPA. PMSCs treated with HNMPA
under muscle diﬀerentiation conditions showed less skeletal
muscle compaction and density at 14 days compared to muscle diﬀerentiation alone, but the addition of IGFBP-6 with
HNMPA showed more muscle compaction as seen with the
white arrows compared to HNMPA alone (20x). The images
are the representative of 3 independent experiments from
one preterm placenta. (Supplementary Materials)
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